The authors transplanted adult bone marrow non hematopoietic cells into the striatum after embolic middle ce rebral artery occlusion (MCAO), Mice (n = 23: C57BLl6J) were divided into four groups: (I) mice (n = 5) were subjected to MCAO and transplanted with bone marrow nonhematopoi etic cells (prelabeled by bromodeoxyuridine, BrdU) into the ischemic striatum, (2) MCAO alone (n = 8), (3) MCAO with injection of phosphate buffered saline (n = 5), and (4) bone marrow nonhematopoietic cells injected into the normal stria tum (n = 5). Mice were killed at 28 days after stroke. BrdU reactive cells survived and migrated a distance of approxi mately 2.2 mm from the grafting areas toward the ischemic areas. BrdU reactive cells expressed the neuronal specific pro tein NeuN in I % of BrdU stained cells and the astrocytic spe-Abbreviations used: BMPs, bone morphogenetic proteins; BrdU, bromodeoxyuridine; DAB, 3,3' -diaminobenzidine; 5-FU, 5-tluoroura cil; GFAP, glial fibrillary acidic protein; H&E. hematoxylin and eosin; HSCs, hematopoietic stem and progenitor cells; MCAO. middle cere bral artery occlusion; MSCs, marrow stromal cells; NSS, neurologic severity score; PBS, phosphate-buffered saline.
Fetal neural stem cells can form new neurons (Gage, 1998; Snyder et. ai., 1997) and reduce behavioral deficits in damaged and compromised animal and human brain (Bjorklund and Lindvall, 1999; Gage, 2000) . A series of patients with Parkinson's disease have been treated with mesencephalic cells from human fetuses obtained from 6-to 9-week-old abortuses (Spencer et ai., 1992; Freed et ai., 1995; Kordower et aI., 1995; Defer et aI., 1996; Lopez-Lozano et aI., 1997) . Some patients exhibited sig nificant improvement of clinical symptoms and synthesis of dopamine as assayed by fluorodopa uptake by posi tron emission tomography (Spencer et aI., 1992; Freed et cific protein glial fibrillary acidic protein (GFAP) in 8% of the BrdU stained cells. Functional recovery from a rotarod test (P < 0.05) and modified neurologic severity score tests (including motor, sensory, and ret1ex: P < 0.05) were significantly im proved in the mice receiving bone marrow nonhematopoietic cells compared with MCAO alone. The current findings sug gest that the intrastriatal transplanted bone marrow nonhema topoietic cells survived in the ischemic brain and improved functional recovery of adult mice even though infarct volumes did not change significantly. Bone marrow nonhematopoietic cells may provide a new avenue to promote recovery of injured brain. Key Words: Bone marrow cells-Transplantation Stroke-Mice. ai., 1995; Kordower et ai., 1995; Defer et ai., 1996) , even 10 years after transplantation (Bjorklund and Lindvall, 1999) . Fetal stem cells implanted into the striatum have also been used to reconstruct damaged basal ganglia cir cuits and to ameliorate behavioral deficits in ischemic rats (Onizuka et ai., 1996; Goto et aI., 1997) . However, there are critical ethical and logistical problems sur rounding the use of embryonic neural stem cells for the treatment of central nervous system diseases. For these reasons, attempts have been made to develop alternative cells for neurotransplantation, such as encapsulated cells, genetically engineered cells, and a variety of transformed cell lines (Kang et aI., 1993; Bankiewicz et ai., 1993; Gage, 1998; Boriongan et ai., 1998) . However, in all of these cases immunorejection is inevitable. Bone marrow is a source of stem cells and may be a better choice for transplantation because issues of rejection have been overcome (Azizi et ai., 1998) .
Hematopoietic stem and progenitor cells (HSCs) resi dent in bone marrow give rise to blood elements and have been genetically altered ex vivo and reimplanted in patients (Karlsson, 1991; Walsh et ai., 1994) . In addition to HSCs, bone marrow also contains a subset of heterogeneous nonhematopoietic cells, isolated by their adherence to plastic, which include marrow stromal cells (MSCs, also referred to as mesenchymal stem and progenitor cells) (Prockop, 1997; Kopen et aI., 1999 , Colter et aI., 2000 .
The nonhematopoietic cells have attracted interest be .cause of their ability to function as a feeder layer for the growth of hematopoietic stem cells, their multipotential ity for differentiation, and their possible use for cell and gene therapy (Pereira et a!., 1995 (Pereira et a!., ,1998 Mason et aI., 1998; Riew et a!., 1998; Prockop, 1998; Bruder et aI., 1998; Horwitz et a!., 1999; Colter et a!., 2000) . Culture expanded MSCs have also been infused into adult cancer patients, opening the door to MSC therapy for a number of diseases (Lazarus et a!., 1995) . Studies indicate that cells derived from bone marrow survive, proliferate, mi grate, and differentiate into glial and neuronal pheno types (Azizi et aL, 1998; Eglitis et a!., 1997 Eglitis et a!., ,1999 Prockop, 1997 Prockop, ,1998 . These data indicate that MSCs are: (I) easy to isolate from the small aspirates of bone mar row that can be obtained under local anesthesia, (2) ca pable of rapid proliferation in culture, (3) amenable to survival and integration in the host brain, and (4) immu nologically inert. Bone marrow nonhematopoietic cells contain stem cells that may serve to replenish lost cells; moreover, they contain a variety of cells that secrete substances that may lead to recovery. Plastic-adherent cells from bone marrow normally support hematopoietic progenitors and secrete a number of hematopoietic cyto kines and trophic factors-for example, interleukins, stem cell factor, and colony-stimulating factor-I (Eaves et a!., 1991; Majumdar et a!., 1998; Colter et a!., 2000) .
Experimental occlusion of the middle cerebral artery (MCA) in animals produces neurobehavioral deficits parallel to those seen in ischemic stroke in human pa tients (Borlongan et a!., 1997) . In the current study, the authors tested the hypothesis that intracranial transplan tation of adult bone marrow nonhematopoietic cells into the adult mouse after stroke survive, migrate, and differ entiate to parenchymal phenotypes. Behavioral tests for functional restoration of ischemic damaged tissue were also scored after MCAO and transplantation, using a ro tarod test and modified neurologic severity score (NSS).
MATERIALS AND METHODS

Preparation of donor bone marrow nonhematopoietk cells
Primary cultured bone marrow cells were obtained from adult mice (C57BL/6J, Jackson Laboratories, Bar Harbor, ME, U.S.A.) receiving 5-fluorouracil (5-FU, 150 mg/kg) intraperi toneally 2 days before harvesting (Randall and Weissman, 1997) . Using a 21-gauge needle connected to a I mL syringe with phosphate-buffered saline (PBS, 0.5 mL), fresh complete bone marrow was harvested aseptically from tibias and femurs. Bone marrow was then mechanically dissociated until a milky J Cereb Blood Flow Metab, Vol. 20, No. 9, 2000 homogenous single-cell suspension was achieved. Red blood cells were removed from bone marrow using 0.84% NH4Cl. Numbers of nucleated marrow cells were measured by a cy tometer, and 2 x 10 6 nucleated cells were seeded into each tissue culture flask in Iscove's Modified Dulbecco's medium supplemented with fetal bovine serum (10%). After 3 days of incubation, cells tightly adhered to plastic and were resus pended to fresh lscove's Modified Dulbecco's medium in new tlasks and were grown for three passages. To identify cells derived from bone marrow, bromodeoxyuridine (BrdU), which labels DNA during the S phase, was added into the medium at 72 hours before transplantation. For immunostaining, the ad herent cells were subcultured in chambered slides.
Embolic MeAO and transplantation
All experimental procedures have been approved by the Care of Experimental Animals Committee of Henry Ford Hospital. Experimental adult mice (C57BL/6J, weighing 27 to 35 g) were subjected to MCAO and transplanted with bone marrow non hematopoietic cells (n = 5). Control mice were subjected to MCAO alone (n = 8), injection of PBS into the ischemic striatum (n = 5), and transplantation of bone marrow nonhe matopoietic cells into the normal striatum (n = 5). Middle cerebral artery occlusion was induced using an embolic model developed in the authors' laboratory (Zhang et aI., 1997) . Briefly, using a facemask, mice were anesthetized with 3.5% halothane and anesthesia was maintained with 1.0% halothane in a 2: I mixture of N20:02. A single intact fibrin-rich 24-hour old homologous clot (8 mm x 0.000625 mm 2 , 0.18 fLL) was placed at the origin of the MCA through a modified PE-50 catheter. Surgical and physiologic monitoring procedures were identical to those previously published (Zhang et aI., 1997) . Transplantation of donors into the striatum was carried out according to the method described by Goto et al. (1997) . Briefly, at 4 days after MCAO (n = 18), mice were mounted on a stereotaxic frame (Stoelting, Wood Dale, IL, U.S.A.).
Using aseptic technique, a burr hole (I mm) was made on the right side of the skull to expose the dura overlying the right cortex. Semi suspended cells (I x 105 in 3 fLL PBS) were slowly injected over a IO-minute period into the right striatum (antero/ posterior = 0 mm, lateral to midline = 2.0 mm, and vertical to dura = 3.5 mm from the bregma) (Franklin and Paxinos, 1997) . This position approximates the ischemic boundary zone in the striatum. The needle was retained in the striatum for an additional 5-minute interval to avoid donor retlux. Immuno suppressants were not used in any animal.
Behavioral tests
Each mouse was subjected to a series of behavioral tests to evaluate various aspects of neurologic function by an investi gator who was blinded to the experimental groups. Measure ments were performed before stroke and at 28 days after stroke. These deficits were various in animals, but primarily consisted of flexion of forelimbs, head moving more than 10° to the vertical axis, and placing test.
Rotarod test. An accelerating rotarod (Stoelting) provides an index of fore and hindlimb motor coordination and balance (Hamm et aI., 1994) . The duration that mice remained on the accelerating rotating rod was measured. The velocity was slowly increased from 4 g to 40 g within 5 minutes. A trial was terminated when the mouse fell from the rotarod. The animals were trained by 5 trials per day for 3 days before MCAO to obtain stable baseline values (in seconds). Motor test data are presented as percentage of mean duration (five trials) on the rotarod compared with the internal baseline values. Startle reflex (a motor response to a brief loud noise from snapping a clipboard paper)
Score
One point is awarded for the inability to perform the tasks or for the lack of a tested reflex. A score of 10 to 14 is severe; 5 to 9 is moderate;
I to 4 is mild injury. The maximum point score is 14.
Modified neurologic severity score. Table I , 1997; Schallert, 1997) . These tests are similar to contralateral neglect testing described in humans (Healton 1982) . The authors defined the severity of injury by the score graded on a scale of 0 to 14 (normal score 0, maximal deficit score 14). One point was awarded either for the inability to perform, or for abnormal task performance, or for the lack of a tested reflex.
Histologic and immunohistochemical assessment
Mice were allowed to survive for 28 days after MCAO when the animals were then reanesthetized with ketamine (44 mg/kg) and xylazine (13 mg/kg). The mouse brains were fixed b y transcardial perfusion with saline, followed by perfusion ana immersion in 4% paraformadehyde. The forebrain was sec tioned into seven equally spaced (I mm) coronal blocks and then the brain blocks were embedded in paraffin. Sections (6-11m thick) were cut from each block in the coronal plane and stained with hematoxylin and eosin (H&E). Sections were traced using the Global Lab Image analysis system (Data Translation, Malboro, MA, U.S.A.). The indirect lesion area, in which the intact area of the ipsilateral hemisphere was sub tracted from the area of the contralateral hemisphere, was cal culated (Swanson et a!., 1990) . The lesion volume is presented as a volume percentage of the lesion compared with the con tralateral hemisphere.
Immunohistochemical staining (Li et a!., 1998b; Li and Chopp, 1999 ) was used to detect cells derived from bone mar row nonhematopoietic cells. Briefly, a series of adjacent 6-f.Lm thick sections (25-f.Lm interval) from each block were analyzed using light and fluorescent microscopy (Olympus, BH-2, Lake Succcess, NY, U.S.A.) and a Bio-Rad MRC 1024 (argon and krypton) laser-scanning confocal imaging system mounted on a Zeiss fluorescent microscope (Bio-Rad, Cambridge, MA, U.S.A.). Cells in chambered slides were fixed with acetone for 5 minutes. To expose the epitope, slides were treated with 50% formamide solution for 30 minutes followed with 2 N HCl for 10 minutes. After blocking in normal serum, sections and cells were treated with the monoclonal antibody against BrdU (di lution I: 100; Calbiochem, San Diego, CA, U.S.A.). After se quential incubation with peroxidase conjugated rabbit anti mouse IgG (dilution 1: I 00; Dakopatts, Carpinteria, CA, U.S.A.), the secondary antibody was bound to the first antibody against BrdU. Diaminobenzidine was then used as a chromo gen. Counterstaining of sections by hematoxylin was also per formed. Cells derived from bone marrow nonhematopoietic cells were identified using morphologic criteria (Pollak and Friede, 1977; Kelemen et a!., 1979; Bonner et a!., 1999) and by BrdU reactivity (the tracer), present only in the donor cells.
To determine the fate of the BrdU positive cells, the authors performed immunoperoxydase and immunofluorescence double labeling for BrdU and for astrocytes specific antibody, glial fibrillary acidic protein (GFAP, dilution 1: 1000; Da kopatts, Carpinteria, CA, U.S.A.). Each coronal section was initially treated by the primary antibody against BrdU, as de scribed above. Sections were then treated with GFAP as the second primary antibody. Fluorescein isothiocyanate conju gated secondary antibody (dilution 1:20; Calbiochem) was added for double-label immunoreactivity identification. Immu nofluorescence double-labeling was used using BrdU-Cy5 (red, Accurate, Westbury, NY, U.S.A.) and NeuN (dilution 1:200; Chemicon, Temecula, CA, U.S.A.)-f1uorescein isothiocyanate (green). Negative control sections from each animal received identical preparations for immunohistochemical staining, ex cept that primary antibodies were omitted. Fluorochromes on the section were excited by the laser beam at 488 nm (Cy5) and 647 nm (fluorescein isothiocyanate), and emissions were ac quired sequentially with a photomultiplier tube through 522 nm and 670 nm emission filters, respectively.
In each animal the authors measured the total number of BrdU reactive cells on 10 sequential slides (25-f.Lm interval) for each block from all 7 blocks (A to G). These sections encom passed the ischemic center and the boundary zone of the dam aged tissue and the transplanted area. The light and fluorescein microscopic features on immunoperoxydase preparation used to identify BrdU positive cells include small and round or oval nucleus with intensely stained chromatin (x 132 magnification of an Olympus BH2). A conservative estimate of the diameter of the bone marrow-derived cells was 12 f.Lm; thus, the total number of BrdU reacti ve cells estimated to be within a I-mm thick block was equal to the average number measured within 10 sections multiplied by the number of l2-f.Lm-thick sections within I mm. The total number of BrdU reactive cells in the whole forebrain was then calculated by adding the numbers of BrdU reactive cells from all 7 blocks. In addition, 6-f. Lm-thick Motor test NSS test (28 da y s) (28 da y s) sections from paraffin D block. corresponding to coronal co ordinates for bregma -0.5�0.5 mm (Franklin and Paxinos. 1997) . was used using double staining. A total of 500 BrdU reactive cells per animal were counted to obtain the percentage of each cell type specific marker (NeuN, GFAP) colocalized with BrdU in cells. The expression of BrdU reactive cells with cell type specific immunoreactivity was quantified by counting at least 10 fields in each slide at a magnification of x 132.
Statistical analysis
The lesion volume, the number of cells derived from bone marrow, and neurologic deficits (the rotarod test and NSS) of mice were subjected to paired t-tests to evaluate differences between control (MCAO alone) and each treatment. Data are presented as mean values ± SD. The level of significance was set s; 0.05.
RESULTS
Donor cells
Cells tightly adhered to the plastic of culture flasks and most were spindle-shaped, but some were round or flat in appearance. These cells replicated for three pas sages as clonal rosettes without changing their morphol ogy (Fig. lA) . BrdU reactive cells (> 90% of all cells) immediately before transplantation are shown in Fig. I B. 
Ischemic tissue
The blood gasses were within normal ranges for all animals and did not differ among groups (data not shown). Within 6-J..L m-thick coronal sections, H&E stain ing indicated that there was no significant gliosis or in filtration of leukocytes around the bone marrow nonhe matopoietic cell transplantation site in all mice. Com pared with control mice (17.5 ± 10.2 mm 3 ) subjected to MCAO alone, transplantation of bone marrow nonhema topoietic cells (16.7 ± 19.4 mm 3 ) did not significantly alter the volume of ischemic damage at 28 days after MCAO. No significant change of the ischemic volume was observed in the mice subjected to MCAO with PBS injection (19.4 ± 18.4 mm 3 ).
Survival, migration, and differentiation of bone marrow-derived stromal cells after intrastriatal transplantation
Within the brain tissue, cells derived from bone mar row were characterized by small nuclei, round-to-oval dark purple by H&E staining, and dark brown nuclei by BrdU staining (Fig. I C) with irregularly shaped and thin cytoplasm. At 28 days after MCAO (24 days after bone marrow cell transplantation), 540 BrdU -labeled cells were detected in the brain of I of 5 mice subjected to bone marrow nonhematopoietic cells transplantation into the normal striatum without MCAO, Scattered BrdU re active cells were only observed along the needle track in the nonischemic brains of the remaining four mice. The numbers of BrdU reactive cells (6,660 ± 2,820) was sig nificantly higher (P < 0.05) in the ischemic mouse brain subjected to MCAO with bone marrow nonhematopoi etic cell transplantation than in the nonischemic mouse brain with MSC transplantation. Approximately 0.5% and 6% BrdU reactive cells were readily detected at one month after transplantation of 1 x 10 5 BrdU labeled cells transplanted into the nonischemic striatum and into the ischemic mouse striatum, respectively.
Cells derived from bone marrow were primarily con centrated within or near the injected site in the striatum (Fig. 1C ). BrdU reactive cells derived from bone marrow migrated into multiple areas of the brain including the corpus callosum and cortex, at a distance of at least 2.2 mm (Fig. 1 D) . Double staining demonstrated that ap proximately 8% (Fig. IE to IF) and 1 % (Fig. 1G to II) of BrdU reactive cells expressed GFAP and NeuN phe notypes, respectively.
Behavioral tests
No significant differences of the rotarod test were de tected among groups before surgery. The rotarod test and NSS demonstrated neurologic and functional deficits re sulting from the MCAO ischemic insult, and no signifi cant differences were noted among groups before trans plantation. Within each group, the behavioral deficits evaluated by the modified rotarod test and NSS after MCAO showed a progressive recovery over time from 1 day to 28 days after MCAO. At 28 days after MCAO, mice transplanted with bone marrow nonhematopoietic cells showed a significant improvement in the rotarod test (P < 0.05; Fig. 2A ) and in NSS (P < 0.05; Fig. 2B ), compared with controls subjected to MCAO alone. Non ischemic mice subjected to transplantation of bone mar row nonhematopoietic cells into the striatum performed all tasks, thus obtaining an NSS of O.
DISCUSSION
The current data demonstrate that adult bone marrow nonhematopoietic cells survive, migrate, and differenti ate into phenotypes of parenchymal cells in the adult mouse brains after ischemia. Intrastriatal transplantation of bone marrow nonhematopoietic cells was effective in reducing ischemia-induced behavioral deficits in mice.
Stem cells are multipotent, that is, they can form dif ferent cell types. Stem cells have been isolated from various tissues in animals and humans, including embry onic (embryo), hematopoietic (bone marrow), mesenchy mal (bone marrow), and even neuronal (adult brain) tis- Vol. 20, No. 9, 2000 sues. Two kinds of stem cells (HSCs and MSCs) localize in normal adult bone marrow. Hematopoietic stem cells provide a continuous source of progenitors for red blood cells, platelets, monocytes, granulocytes, and lympho cytes. Marrow stromal cells readily differentiate into os teoblasts, chondroblasts, adipocytes, and even myoblasts and brain glial cells (Vogel, 2000; Prockop, 1997) . Mar row stromal cells have several advantages over HSCs (unpublished data, 2000) for use in cell therapy after MCAO. The fraction of HSCs of fresh bone marrow cells placed into culture was relatively high. Most of the HSCs were lost as the bone marrow cells were maintained as primary cultures for 2 or 3 weeks, and HSCs were dif ficult to expand in culture. Hematopoietic stem cells did not express neural phenotypes in ischemic mouse brains at 28 days after transplantation. Bone marrow nonhema topoietic cells are easily isolated in the medium by their tendency to adhere to plastic and readily proliferate in culture. Gage et al. (1995) indicate that stem cells from one region will, when transplanted to ectopic central nervous system sites, differentiate with a terminal phenotype ap propriate for that ectopic site. Importantly, a lesioned central nervous system is a different environment than an intact central nervous system and markedly alters the terminal differentiated phenotype of the transplanted cells (Gage et aI., 1995) . In their studies, neuronal dif ferentiation was restricted to the lesioned area. In the current model, the authors found that MSCs retained the capacity to respond to local epigenetic signals in the nonischemic and ischemic brain, as MSCs can survive and differentiate into neuronal (NeuN) and glial cell (GFAP) phenotypes. In all ischemic mice, the sum frac tion of double-labeled cells was -1 % BrdU-NeuN and -8% BrdU-GFAP.
BrdU reactive cells survive and differentiate not only in the ischemic brain, but they are also present in the brain without ischemia. The current data indicate that -0.5% of BrdU reactive cells survive at 24 days after injection into the normal striatum of a mouse. The sur vival rate, however, is less than the -20% of adherent heterogeneous bone marrow cells reported to survive at 30 days after striatal implantation in normal rats (Azizi et aI., 1998) . The small number (-0.5%) of BrdU reactive cells that survive in the normal mouse brain might be because of the possibility that infused cells divide rapidly and consequently dilute the label below levels of detec tion of BrdU, or because of the different animal strains used. However, the small number of BrdU-Iabeled cells is more likely attributed to the fact that the transplanted bone marrow nonhematopoietic cells are a heteroge neous population containing few MSCs. Phinney et al. (1999) and Kopen et al. (1999) recently reported a method to eliminate unwanted adherent cells from the cul tures through immunodepletion. After immunodep1etion, MSCs appear as a uniform population of fibroblastoid shaped cells that are devoid of CD 11 b or CD45 expres sion (cell surface receptors of myelopoietic cells). They estimate that MSCs represent only 10% to 20% of the total cell population in plastic adherent marrow cell cul tures. Despite the heterogeneous nature of these cultures, the ischemic microenvironment appears to influence and facilitate bone marrow derived stromal cell survival and proliferation. The ischemic boundary zone is threatened tissue. This ischemic boundary zone expresses develop mental genes and proteins (Li and Chopp, 1999) . The current data demonstrated that the BrdU reactive cells were highly concentrated in the ischemic boundary zone after MCAO. Molecules expressed in the ischemic boundary zone might play a role in the subsequent sur vival and differentiation, or migration, or both, of trans planted bone marrow nonhematopoietic cells.
The current data indicate that intrastriata1 transplanta tion of bone marrow nonhematopoietic cells improves behavioral restoration after ischemia in mice. These data were consistent with earlier reports showing that grafts of fetal striatal cells implanted into the caudatoputamen partially restore function after stroke (Aihara et aI., 1994; Nishino et aI., 1993) . The authors used two tests (the rotarod test and NSS) to detect the neurologic behavioral responses to experimental ischemia in the mice. The ro tarod test is a well-established procedure for testing limb motor coordination and balance aspects of motor perfor mance in mice. In the current study, the authors con firmed that the accelerating rotarod task is a sensitive index to detect mild motor deficits at one month after the onset of ischemia with bone marrow nonhematopoietic cell transplantation. Similar to the rotarod test, the NSS can be used to assess mild motor, sensory, and reflex deficits after stroke. The NSS is an economical, simple, and rapid test for animals in characterizing the asymmet ric behavior in unilateral damage.
Bone marrow nonhematopoietic cells contain stem cells that may serve to replenish lost cells in the ischemic damaged brain, and they contain a variety of cells that secrete substances that may lead to recovery. However, in the current study, the authors could not directly relate numbers of BrdU labeled cells to functional improve ment. At this point, observations are limited to survival, migration, and differentiation of BrdU labeled cells, and the improvement of functional outcome with bone mar row nonhematopoietic cell transplantation. However, it is unlikely that the approximate 6,660 cells derived from bone marrow that survive and -I % and -8% of BrdU reactive cells with neural phenotypes of NeuN and GFAP were capable of providing behavioral improve ment in mice treated with MSCs after MCAO. The study by Horwitz et al. (1999) provides a first glimpse of the therapeutic potential of a small fraction of MSCs in pa-tients with osteogenesis imperfecta. To explain how the presence of only 1.5% to 2.0% donor mesenchymal cells in their study could lead to improvement in behavioral recovery, they indicate that perhaps the recipients are gradually replacing the abnormal matrix with normal collagen produced from the rare donor cells. Interaction of transplanted tissue with the host brain may also lead to production of trophic factors (Un sicker, 1993 (Un sicker, ,1994 . This suggests that bone marrow nonhematopoietic cells may secrete neurotrophins in the ischemic brain. Bone marrow nonhematopoietic cells normally support hema topoietic cells and bone cells and secrete a number of hematopoietic cytokines and factors, for example, bone marrow nonhematopoietic cells express bone morphoge netic proteins (BMPs) (Bi et aI., 1999) . Recent studies demonstrate that BMPs trigger neuronal differentiation of neocortical precursors within the ventricular zone (Li et aI., 1998a) . The bone marrow nonhematopoietic cells secrete colony-stimulating factor-I, interleukins, stem cell factor, and other hematopoietic regulatory molecules (May singer et aI., 1996; Eaves et aI., 1991) . The hema topoietic cytokine colony-stimulating factor-l is a growth factor in the central nervous system (May singer et aI., 1996) . In summary, the current data indicate that bone marrow nonhematopoietic cells transplanted into brain generate neural-like cells and promote the recovery of neurologic deficit.
